Unicycive Therapeutics Inc UNCY

Healthcare Biotechnology

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

NDAQ:UNCY - Post by User

Unicycive Therapeutics Inc > UNCY .....The trend continues....Day 6 of run....Sheesh

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Mar 10, 2023 9:04am

64 Views

Post# 35330111

UNCY .....The trend continues....Day 6 of run....Sheesh

Close Prices Last 3 Months

Price/volumes not adjusted for restructures

Date	Ex	Sym	Open	High	Low	Close	Chg	Vol	#Tr	Bid	Ask
2023-03-09	Q	UNCY	1.91	2.24	1.76	2.06	0.44	46,695,686	51,175
2023-03-08	Q	UNCY	1.44	1.75	1.35	1.62	0.12	12,134,258	14,231
2023-03-07	Q	UNCY	1.46	2.16	1.37	1.50	0.26	89,437,509	103,573
2023-03-06	Q	UNCY	1.41	1.63	1.13	1.24	0.75	102,922,506	98,143
2023-03-03	Q	UNCY	0.511	0.52	0.48	0.49	-0.01	70,241	107